All episodes

S6.14.3 - Louise and Roger React to Empowered SLD Patient Advocates

S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program

S6.14.1 - How the Harrison Patient Advocacy Fellowship Came To Be

S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program

S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism

S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease

S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management

S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health

S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?

S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices

S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US

6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative

6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach

6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics

6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases

6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients

6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic

6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans

6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening

6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research

6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge

6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play

6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd

6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects

6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed

6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change

6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment

S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development

S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care

S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care

S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development

S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH

S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom

S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science

S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis

S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies

S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment

S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates

S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future

S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy

S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs

S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic

S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies

S6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves

S6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn"

S6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom

S5 - E26.5 - Looking Back at #TLM2024 - Promoting Healthy Livers and Looking Ahead to 2025

S5 - E26.4 - Looking Back at #TLM2024 - Patient Advocacy and Patient-Centric Trials

S5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA Corner

S5 - E26.2 - Looking Back at #TLM2024 - Patient Genotyping and MASH Clusters

S5 - E26.1 - Looking Back at #TLM2024 - Semaglutide Passes the ESSENCE Test

S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024

S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom

S4 - E24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication

S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI

S5 - E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways

S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

S5 - E24.1 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Takeaways

S5 - E24 - A view of MASLD: Looking back at EASL Congress from six weeks later

S5 SPECIAL 5 - Reviewing EASL Congress: Louise Campbell 3 (first-time material)

S5 SPECIAL 4 - Reviewing EASL Congress: Sven Francque

S5 SPECIAL 3 - Reviewing EASL Congress: Louise Campbell 2

S5 SPECIAL 2 - Reviewing EASL Congress: Louise Campbell I

S5 SPECIAL 1 - Reviewing EASL Congress: Mike Betel

S5 - E23.6 - From The Vault: Improving Patient Self-Management And Key Takeaways On Nutrition For MASH Resolution

S5 - E23.5 - From the EASL Congress: The Need for Shared Experience MASLD Support Groups and Programs

S5 - E23.4 - From the EASL Congress: Socioeconomic And Psychological Issues In The Physician-Patient Dialogue

S5 - E23.3 - From The EASL Congress: Improving The Physician-Patient Dialogue

S5 - E23.2 - From The EASL Congress: Dynamics Of The Physician-Patient Dialogue

S5 - E23.1 - From The EASL Congress: Overview Of Challenges In Physician-Patient Communication

S5 - E23 - Lessons from EASL Congress: Challenges in Provider-Patient Communication

S5 - E22.6 - FROM THE VAULT: Patient Advocates Reflect On How The "System" Views MASH

S5 - E22.5 - Healthy Livers, Healthy Lives: Watershed Moments To Come In MASLD Publlc Policy

S5 - E22.4 - Healthy Livers, Healthy Lives: The Role Of The Updated EASL MASLD Guidelines And Big Data

S5 - E22.3 - Healthy Livers, Healthy Lives: Challenges and Promise in Building a Global MASLD Health Policy

S5 - E22.2 - Healthy Livers, Healthy Lives: "Political Will" In MASLD Public Policy

S5 - E22.1 - Healthy Livers, Healthy Lives: Why MASHville Needs This Coalition

S5 - E22 - Healthy Livers, Healthy Lives: A Global SLD Public Health Coalition

S5 - E21.6 - From The Vault: Comments On The 2023 AASLD Revised Practice Guidance

S5 - E21.5 - The Updated MASLD CPG: Implications For Healthcare Systems

S5 - E21.4 - The Updated MASLD CPG: Pharmacology And New Educational Needs

S5 - E21.3 - The Updated MASLD CPG: Screening, Diagnosing And Managing Patients

S5 - E21.2 - The Updated MASLD CPG: Benefits Of The Collaboration

S5 - E21.1 - The Updated MASLD CPG: Introductions

S5 - E21 - Reviewing The Updated ESL-EASD-EASO MASLD Clinical Practice Guidelines

S5 - E20.6 - From the Vault: FGF-21s and "Twin-cretins" At EASL Congress 2023

S5 - E20.5 - Drug Development Highlights From EASL Congress 2024: Denifenstat, SPECIAL and Other Stories

S5 - E20.4 - Drug Development Highlights From EASL Congress 2024: Are FGF-21s Induction Therapy or a "MASH Cure"?

S5 - E20.3 - Drug Development Highlights From EASL Congress 2024: "Twin-cretins" and efruxifermin

S5 - E20.2 - Drug Development Highlights From EASL Congress 2024: Tirzepatidate and other "Twin-cretins"

S5 - E20.1 - Drug Development Highlights From EASL Congress 2024: Resmetirom

S5 - E20 - Lessons From EASL Congress 2024: Exciting Advances in Drug Development

EASL Congress 2024: Interviews From A Seminal Meeting For MASLD & MASH

S5 - E18.5 - How Listeners Can Support HOPE, A Unique Support Community For People Who Have Harmed Their Bodies Through Alcohol Use Disorder

S5 - E18.4 - The Future Of HOPE: Expanding the Support Community for Patients Who Have Harmed Their Bodies Through Alcohol Use Disorder

S5 - E18.3 - Specific Support Elements HOPE Provides For People Who Have Harmed Themselves Due To Alcohol Use Disorder

S5 - E18.2 - Why People Who Have Harmed Themselves Through Alcohol Use Disorder Need HOPE

S5 - E18.1 - Introducing HOPE, A Project For People Who Have Harmed Their Bodies Through Alcohol Use DIsorder

S5 - E18 - Introducing HOPE, a support program for patients living with the effects of ALD and cirrhosis